A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Clinical trial NCT05803421 · COMPLETED

Trial details

NCT number: NCT05803421
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Type 2 Diabetes Obesity Overweight or Obesity Overweight Cardiovascular Diseases Chronic Kidney Disease

Start date: 2023-04-03
Primary completion: 2026-03-16
Enrollment: 2749

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.